

## TRANSFUSION MEDICINE SERVICES

<b>OTHER NAMES</b> IMIG/IVIG	<b>CLASSIFICATION</b> Immunglobin	<b>ALERTS</b> Contains human plasma
---------------------------------	--------------------------------------	--

### PREPARATION and ADMINISTRATION

**Reconstitution** None.

VariZIG is a sterile solution of immune globulin for intramuscular or intravenous injection. It is a clear or opalescent liquid. Do not use product that appears cloudy or contains deposits.

#### Intramuscular Injection

Administer intramuscularly, preferably in the anterolateral aspects of the upper thigh and the deltoid muscle of the upper arm.

The gluteal region should not be used routinely as an injection site because of the risk of injury to the sciatic nerve.

Doses can be divided and injected into several muscle sites to reduce local pain and discomfort.

#### IV Direct

If VariZIG is administered by an IV route, then drug should be infused into a suitable vein over 3–5 minutes.

### Requirements and Monitoring

**Pre and post injection vitals** Following intramuscular (IM) or intravenous (IV) administration of VariZIG, patients should be kept under observation for at least 20 minutes for monitoring of potential adverse effects.

Blood pressure via cuff or arterial line

Temperature

Heart Rate

Respirations

Lung sounds in non-verbal, non-oriented or pediatric patients and patients with CHF or pulmonary dysfunction

Keep unopened back up bag of NS and standard IV tubing nearby for prompt response if an adverse event (AE) occurs.

### INDICATIONS

Prevention or reduction in severity of maternal infections within 4 days of exposure to the varicella zoster virus.

Pregnant women may be at a higher risk of complications from chickenpox than healthy adults. The decision to administer VariZIG to a pregnant woman should be evaluated on an individual basis.

### ADVERSE EFFECTS

**Adverse reactions may include:** Allergic-type hypersensitivity reactions including anaphylaxis have been reported and have manifested as pruritus, rash, urticaria, local site reactions, hives, facial swelling, dizziness, hypotension, nausea, chest discomfort, cough, dyspnea, wheezing, flushing, discomfort (generalized) and fatigue.

**If an AE is suspected:** Consult the authorized prescriber (AP) for medical management. Notify the TM lab of a suspected reaction.

- Review the product lot number, TM tag and patient ID to rule out a verification (clerical) error and that the expiry date and time has not passed.

TRANSFUSION MEDICINE SERVICES

<b>OTHER NAMES</b> IMIG/IVIG	<b>CLASSIFICATION</b> Immunglobin	<b>ALERTS</b> Contains human plasma
---------------------------------	--------------------------------------	--

- Ensure TM tag, along with a copy of the documented clinical data and interventions are sent to TM lab if an adverse event occurs.

Note: AP may require blood work

**DOSAGE**

Dosing of VariZIG is based on body weight. The recommended adult dose is 125 units/10 kg body weight up to a maximum of 625 units. The maximum dose of 625 units (5 vials) should be administered for all patients greater than 40 kilograms in weight. Each 1.2 mL vial contains 125 units of IG.

**COMPATIBILITY, STABILITY**

- Single use vials. Do not use past expire date
- Do not dilute
- Protect vials from light
- Do not store unused vials in refrigerator. Administer at room temperature

**DOSAGE FORMS**

- Supplied by Transfusion Medicine

**MISCELLANEOUS**

- None

**RECONSTITUTION**

- Not applicable

**REFERENCES**

- [CL-BP-030, IWK-625 Blood Component and Blood Product Administration – Policy and Procedure](#)
- VariZIG product monograph. Found at <https://www.kamada.com/products/?productType=0&productArea=0>